Protocol #: 18-274
Status
Recruiting
Description
This research study is studying a drug called M6620 as a possible treatment for advanced solid tumor.
Condition
Solid Tumor
Leiomyosarcoma
Osteosarcoma
Interventions
M6620
Phase
Phase 2
Study Type
Interventional
Further Study Details
Primary Outcome:
Changes in Phospho-Chk1 levels in biopsy specimens
Change in yH2AX levels in biopsy specimens
Disease Control Rate
Secondary Outcome:
Number of participants with treatment related Serious Adverse Events
Estimated Enrollment
223
Study Start Date
January 8, 2019
Eligibility
Gender: All
Minimum Age: 12 Years
Maximum Age: N/A
Health Volunteers: No
Criteria
Massachusetts General Hospital
Information Provided By
Massachusetts General Hospital
Official Title
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
Clinicaltrials.gov Identifier
NCT03718091

 

 

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.

Back to Top